Hagens Berman Investigates Impact of FDA Abiomed Impella Statements, Reminds Investors of Jan. 15, 2013, Lead Plaintiff Deadline in Securities Class Action

SEATTLE - (BUSINESS WIRE) - Hagens Berman today announced that newly published materials for the upcoming Food and Drug Administration's (FDA) Circulatory System Devices Panel meeting raise new issues regarding Abiomed, Inc. (NASDAQ: ABMD) ("Abiomed" ) discussions with the FDA concerning the safety and effectiveness of the Impella 2.5 for high-risk PCI and Abiomed's marketing practices. The firm also advises investors who purchased Abiomed stock between Aug. 5, 2011 and Oct. 31, 2012 (the "Class Period" ) of the Jan. 15, 2013 deadline for moving to be lead plaintiff in a proposed class-action lawsuit against Abiomed regarding alleged securities law violations.

Investors with significant losses who purchased or otherwise acquired Abiomed stock during the class period are encouraged to contact Hagens Berman to discuss moving for lead plaintiff in the pending class-action lawsuit. Investors can contact Hagens Berman Partner Reed R. Kathrein, who is leading the firm's investigation, by calling (510) 725-3000 or by emailing ABMD@Hbsslaw.com.

Any member of the proposed class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Class members need not seek to become a lead plaintiff in order to share in any possible recovery.